Advertisement
Home »

Can ctDNA-Directed Therapy Improve Outcomes in Low-Risk Colon Cancer?

Feb 08, 2024

REFERENCES & ADDITIONAL READING

Morris VK, et al. Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study. Abstract 6, ASCO Gastrointestinal Cancers Symposium 2024, January 18-20, 2024, San Francisco, CA, USA.

 

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement